Maxim Group analyst Jason McCarthy maintained a Buy rating on SELLAS Life Sciences Group Inc (SLS) today and set a price target of $5. The company’s shares opened today at $2.26, close to its 52-week low of $0.80.
“Sellas announced additional data from a preplanned secondary efficacy analysis of the P2b study of nelipepimut-S vaccine (NeuVax, NPS) combined with Herceptin (traztuzumab) in triple negative breast cancer (TNBC) at the SITC meeting taking place Nov. 7-11, Washington DC.”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 5.3% and a 40.9% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as ContraVir Pharmaceuticals Inc, Sonoma Pharmaceuticals Inc, and Aridis Pharmaceuticals Inc.
Currently, the analyst consensus on SELLAS Life Sciences Group Inc is a Moderate Buy with an average price target of $9, representing a 298.2% upside. In a report issued on November 1, Oppenheimer also initiated coverage with a Buy rating on the stock with a $13 price target.
The company has a one-year high of $12.01 and a one-year low of $0.80. Currently, SELLAS Life Sciences Group Inc has an average volume of 1.73M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
SELLAS Life Sciences Group, Inc. operates as a clinical stage biopharmaceutical company, which focuses on the development and commercialization of novel cancer immunotherapeutic for a broad range of indications. Its product galinpepimut-S, or GPS, is an immunotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, which targets the Wilms tumor 1, or WT1, protein. The company was founded on April 3, 2006 and is headquartered in New York, NY.